(Q34390398)

1 August 2017

1 reference

title

Treatment of viral hepatitis--2001. (English)

1 reference

1 August 2017

S C Gordon

1

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 September 2001

1 reference

1 August 2017

1 reference

1 August 2017

volume

33

1 reference

1 August 2017

issue

6

1 reference

1 August 2017

page(s)

385-390

1 reference

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F07853890108995951

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890108995951

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890108995951

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890108995951

Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890108995951

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890108995951

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890108995951

Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890108995951

The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890108995951

Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890108995951

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890108995951

Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890108995951

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890108995951

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890108995951

Management of hepatitis B: 2000--summary of a workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890108995951

10.3109/07853890108995951

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference